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Purpose: Interleukin-17 (IL17) is a novel T helper cell-associated cytokine recently found to be present at high levels in both herniated and degenerate tissues of the intervertebral disc (IVD). IL17 and other Th17-related cytokines are known regulators of inflammation in multiple autoimmune diseases, suggesting their potential involvement in regulating IVD pathology. The objective of this study is to determine the effects of IL17 and a potent co-stimulant, interferon (IFNγ) on human cells from degenerated IVD sources. An ability for IL17 with IFNγ to promote inflammatory cytokine and mediator expression was assessed in IVD cells and compared to effects of another potent pro-inflammatory cytokine, TNFα. Methods: Human IVD cells were isolated from to-be discarded tissues from patients undergoing surgery for degenerative IVD pathology (n=4). Cells of the anulus fibrosus (AF) region were plated at 25,000 cells per well (96-well plates, n=4 wells per group) and overlaid with 150 μL of medium overnight (5% CO 2 , 37°C). Media was then replaced with new media supplemented with one of the following cytokine concentrations: media alone Abstract 498 - Figure 1 . NOx (LEFT) and PGE2 (RIGHT) production by AF cells from 4 degenerative human tissue samples after treatment with control media or media with IL-17, IFNγ, or both IL-17 and IFNγ. The values for the media control only were indicated as dotted horizontal lines.
(control), TNFα (25 ng/mL), IL17 (10 ng/mL), IFNγ (200 U/mL) or both IL17 and IFNγ. After 72 hours, the supernatant was evaluated for release of nitric oxide (NOx, Griess reaction) and prostaglandin E2 (PGE2, ELISA). One-way ANOVA and post-hoc Dunn's analysis evaluated differences amongst treatment groups for NOx and PGE2 release (p=0.05). Results: Stimulation of AF cells with IL17 or IFNγ alone did change NOx levels from control values; however, a significant variability in NOx responses was observed across human subjects (Figure 1 left) . In the presence of IFNγ costimulant, IL17 induced average 2-fold increase in NOx production above that of IL17 alone (IL17: average NOx = 22 μM, IL17 + IFNγ: NOx = 45 μM, Figure 1 left). In contrast, stimulation with IL17 alone led to a significant elevation in PGE2 levels in all 4 samples (average 14fold increase, Figure 1 right) . As for the NOx result, co-stimulation with IL17 and IFNγ led to a large increase in PGE2 release, more than 24-fold over control values (Figure 1 right, IL17 + IFNγ PGE2 release = 1.36 ng/ml; Control PGE2 release = 0.06 ng/ml). In general, the induction of NOx and PGE2 release by IL17 and IFNγ co-stimulation was significantly larger than that due to TNFα stimulation, for which few changes in NOx and a 10-fold increase in PGE2 was observed.
Conclusions:
The results of this study demonstrate that degenerative human IVD cells may respond to IL17 stimulation with increased production of the inflammatory mediators, PGE2 and NOx, with a more robust effect observed in the presence of IFNγ. Degenerative and herniated IVD explants are known to contain IFNγ, and IFNγ is known to act synergistically with IL17 to promote release of inflammatory mediators in other cell types. This work demonstrates that the responsiveness of IVD cells to IL17 and IFNγ is consistent with other cell types, and suggests a potential role for these cytokines in contributing to IVD pathology.
SUSTAINED RELEASE OF SFLT01 IS NECESSARY AND FEASIBLE FOR PROLONGED INTRAARTICULAR DELIVERY TO THE KNEE TO NEUTRALIZE VEGF LOCALLY
D. Li 1 , D. Raitcheva 1 , M. O'Callaghan 1 , N. Moran 1 , J. Serriello 1 , E. Johnston 2 , D. Gianolio 2 , K. Albee 1 , J. Kingsbury 1 , J. Bird 1 , R. Simler 1 , W. Brondyk 1 , K. Culm-Merdek 1 , K. Barranco 1 , B. Greene 1 , G. Matthews 1 1 Genzyme Corp., Framingham, MA; 2 Genzyme Corp., Waltham, MA Purpose: We hypothesize that osteoarthritis (OA) pain-associated bone marrow lesions, effusion, and synovitis are driven pathophysiologically by VEGF mediated increases in vascular permeability, and that local inhibition of VEGF will alleviate OA pain by decreasing incidence and severity of these abnormalities. Our previous work demonstrated that VEGF inhibition using virally delivered soluble Flt receptor (sFlt) decreased synovitis and pain marker expression in a rabbit OA model. In an effort to move from viral mediated proof of concept to development of a protein therapeutic, we determined in rats and rabbits the intraarticular pharmacokinetics of sFlt01, a VEGF neutralizing Fc fusion protein, and subsequently the feasibility of sustained release formulation for prolonging residence time in the joint at or above therapeutic levels for 30∼90 days. N-methyl pyrollidone/poly(lactic acid) (NMP/PLA) depot is considered here as the formulation strategy. Methods: Iodinated sFlt01 PK in rat: 65ug 125 I-sFlt01 was intraarticularly administered to rat knees 4 weeks after meniscectomy surgery. Radioactivity of the knee joints was measured at sacrifice 1, 6, 24, 72, and 144hrs post injection. sFlt01 PK in rabbit: 150ug sFlt01 was intraarticularly administered to rabbit knee 4 weeks after ACL surgery. Rabbits were sacrificed at 6hr, 8hr, 24hr, 18hr, and 48hr post injection. sFlt01 level in serum, urine, synovial fluid, articular cartilage and synovium was quantified by ELISA. sFlt01 sustained release: NMP/PLA depots were formed by dissolving PLA in NMP in a 40:60 w:w ratio. Lyophilized sFlt01 was added to a concentration of 0.8-1.7 w% and dispersed by sonication. Depots were formed by pipetting ∼10ug of material into PBS, allowing the NMP to dissipate and the depot to solidify. In vitro release was conducted under physiologic conditions (PBS + Tween 20, 37°C). Drug release was quantified by BCA. VEGF binding activity was assessed by Biacore and ELISA. Results: Iodinated sFlt01 PK in rats: The knee joint terminal half life of sFlt01 is estimated to be 11 hours in OA rats. There is a very small shift in terminal elimination half life of sFlt01 in joint between OA rats and non-OA rats. sFlt01 PK in rabbits: In general, terminal elimination half life of sFlt01 in joint synovial fluid, synovium and cartilage is very similar in OA and non-OA groups. Exposure in joint synovial fluid, synovium, and cartilage is higher in non-OA group than that in OA group. Systemic exposure in the serum is comparable between OA and non-OA animals. Absorption of sFlt01 into systemic circulation appears to be very slow. sFlt01 is not detected in urine, kidney, heart, liver and lung. sFlt01 sustained release: The NMP/PLA depot showed a nonlinear release pattern with ∼15% released in 26 days. sFlt01 released from NMP/PLA depots demonstrated the ability to neutralize VEGF, as determined by an ELISA assay. Biacore studies showed that sFlt01 released from NMP-PLA depots lost some capacity to bind to protein A, indicating modification to the Fc portion, but that captured sFlt01still strongly bound VEGF. Conclusions: Joint half-life of sFlt01 is as short as hours, suggesting that sustained release formulation is necessary to prolong sFlt01 residence time in the joint. NMP/PLA depots were shown to deliver sFlt01 for ∼30 days. New formulations will be in need to further prolong release, characterize late stage burst and sFlt01 alterations, and to test pharmacokinetics in vivo. Purpose: There are no proven therapies that modify the structural changes in osteoarthritis (OA). Preclinical data suggests that intra-articular recombinant human Osteogenic Protein-1 (OP-1) has reparative effects on cartilage, as well as on symptoms of joint pain. The objective of this study was to determine the safety and tolerability as well as dose-limiting toxicity and maximal tolerated dose of intra-articular OP-1. The secondary objectives were to determine the symptomatic responses through 24 weeks. Methods: This was a Phase 1, double-blind, randomized, multicenter, placebo-controlled, single-dose escalation safety study consisting of 4 dosing cohorts in participants with knee OA. Each cohort was to consist of 8 treated subjects, with treatment allocation in a 3:1 active (of intra-articular OP-1 (also called BMP-7)) to placebo ratio. Eligible subjects were persons with symptomatic radiographic knee OA aged over 40 years. The primary objective of this study was to determine the safety and tolerability including laboratory assessments, immunogenicity data and radiographic assessments. Secondary objectives were to determine the proportion of subjects with a 20%, 50%, and 70% improvement in the WOMAC pain and function subscales at 4, 8, 12, and 24 weeks. Other secondary outcomes included the change from baseline to 4, 8, 12, and 24 weeks for the subscales of the Knee and Osteoarthritis Outcome Score (KOOS) survey, patient global, physician global, quality of life from the SF-36 and the OARSI responder criteria. Results: The mean age of participants was 60 years and 73% were female. All 33 subjects who were enrolled completed the study, most adverse events were mild or moderate and were similar in placebo and OP-1 groups. The 1mg OP-1 group showed a higher frequency of injection site pain and there was no ectopic bone formation seen on plain x-rays. Most subjects in both the OP-1 and placebo groups experienced a 20% improvement in pain and by 12 Weeks, the OP-1 group was similar to placebo. In the participants who received 0.1mg and 0.3mg OP-1, there was a trend toward greater symptomatic improvement than placebo. The other secondary endpoints showed similar trends including the OARSI responder criteria for which the OP-1 groups had more responders than placebo (see table) .
SYMPTOMATIC OUTCOMES IN A PHASE 1 SAFETY AND TOLERABILITY STUDY OF OP
Week 4 3 (42.9%) 4 (66.7%) 1 (16.7%) 2 (33.3%) 10 (40%) 1 (12.5%) Week 8 3 (42.9%) 4 (66.7%) 2 (33.3%) 2 (33.3%) 11 (44%) 0 (0%) Week 12 1 (14.3%) 4 (66.7%) 2 (33.3%) 1 (16.7%) 8 (32%) 1 (12.5%) Week 24 1 (14.3%) 5 (83.3%) 2 (33.3%) 1 (20%) 9 (37.5%) 1 (12.5%)
Conclusions:
There was no dose limiting toxicity identified in this study. The overall trend for OP-1 symptom response was better than placebo with the 0.1 and 0.3 mg groups. The bell shaped dose response curve is consistent with pharmacodynamic studies in pre-clinical models. This symptom response, together with the lack of dose limiting toxicity provide further support for the continued development of this product for treatment of osteoarthritis. 
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